Member Info for Moneymunch

And this one? :-)

9.3218849

VARIANTS OF SIRT6 FOR USE IN PREVENTING AND/OR TREATING AGE-RELATED DISEASES

CA - 17.11.2022

Int.Class

C12N 15/113

Appl.No 3218849

Applicant UNIVERSITY OF ROCHESTER

Inventor GORBUNOVA, VERA

The present invention relates to an isolated nucleic acid molecule encoding a variant of sirtuin 6 (SIRT6) having at least 75% identity with sequence SEQ ID NO: 1, the variant having at least one mutation selected in the group comprising or consisting of a N308K substitution and a A313S substitution with respect to sequence SEQ ID NO: 1. The invention provides means for the regulation of ageing, and/or senescence, and/or lifespan in an individual. The invention further provides means for the repair of double strand breaks in a cell. Finally, the invention also provides means for the prevention and/or the treatment of an age-related disease.

12 months since a crucial patent application, not just for Genflow but a breakthrough for gene therapy and longevity research according to Eric, which could add massive value if awarded. It can take up to 2 years for approval, but the US Patent Office can award within 12 months if accelerated, and so news at anytime which would be truly transformational for all concerned. Gla :-)

"Genflow has expanded its intellectual property portfolio with a provisional patent application focusing on the SIRT6 gene editing. If granted, this patent could mark a significant breakthrough in gene therapy and longevity research."

1.20230018934

METHOD OF IN VIVO ADMINISTRATION OF THE CODING SEQUENCE OF THE SIRT6 GENE VIA ADENO-ASSOCIATED VIRUS

US - 19.01.2023

Int.Class

A61K 48/00

Appl.No 17865688

Applicant GENFLOW BIOSCIENCES SRL

Inventor Eric LEIRE

Methods for in vivo administration of the coding sequence of the sirt6 gene. In particular, methods that include the administration of adeno-associated virus vectors or recombinant adeno-associated virus vectors including the coding sequence of the sirt6 gene.

3p plus next stop with more of the same tomorrow with any luck. Gla holders...more good news at anytime. :-)

Still very much under the radar and still cheap as chips, the timing of today's news missed by many and so just the start of some serious UPside, especially as more positive newsflow is very likely in the near term pipeline. Gla holders :--)

0  0 0

Let's hope Eric has a wad of positive newsflow to deliver in the coming days and weeks...Gla holders...On and UP!!! ;-)

C'mon Eric, let's make 2024 a "Bright" one!!! Tick Tock. Gla ;-)

GenFlow Biosciences

1,411 followers

17m

With the New Year in full swing, it's easy to want to cheat on any goals you may have set for prolonging your #healthspan. Check out what this article by a Harvard nutrition expert about a few simple ways you can eat for longevity 🧬 “Longevity, of course, is influenced by many factors,” says Dr. Frank B. Hu, a professor of nutrition and epidemiology at the Harvard T.H. Chan School of Public Health.“But diet is one of the most important factors that can impact chronic disease risk, mortality and longevity.”

Read more here: hTtps://loom.ly/Ir5B7vA #GenFlowBiosciences #ageing #GENF

Hot off the press, €8.1m awarded to PDC , so hopefully Genflow's next on the list.

https://www.businesswire.com/news/home/20240117630349/en/PDC*line-Pharma-and-Partners-Receive-%E2%82%AC8.1M-From-Walloon-Region-and-Wallonia-Health-Cluster-BioWin-for-Personalized-Therapeutic-Vaccine-Project

Thanks for posting it from the Telegram group ( I'm not a member) all very encouraging for the delivery of some very good news.

0  0 0

Eric confirmed in his August/September interview that Genflow are in negotiation for two non-dilutive research grants which would provide funds for 80% of their R & D for an additional 3 years, fully cashed well into 2026, and so confrmation news in the pipeline along with an update on their Werner Syndrome accelerated clinical plans highly likely. Gl :-)

Nice on Northeast, a great find and thanks for posting. Excitement building. Gl :-)

The Company is headquartered in London and has a Belgian R&D subsidiary, Genflow Biosciences SRL (“Genflow BE”) that was established in 2020. Genflow BE’s location enables it to benefit from the relatively low operating costs and from substantial (non diluting) grants that support its research and development that are available from Belgium’s Wallonia region.

In addition to pre-clinical activities, Genflow seeks an earlier path to revenue with respect to Werner Syndrome, a rare progressive disorder characterised by the appearance of unusually accelerated ageing.

Genflow intends to conduct a European Phase I/II clinical trial with Werner Syndrome patients. The Company believes that positive clinical data will be the source of significant value creation through, potential acquisition or licensing arrangements. Moreover, a trial in Werner Syndrome will support the path to a specific aging indication.

Ps the Estee Lauder connection is very interesting and potentially very exciting considering Genflow's GF-3001 for Werner Syndrome ( premature ageing disease ) is a Topical delivery of Sirt6 directly to the skin, and so endless opportunities and potential in all aspects of age reversal. Gla :-)

Cheers Northeast, anytime now and hopefully the start of a great year ahead for all invested as positive newsflow is delivered, and yes indeed Porter, any association with Estee Lauder's longevity aspirations involving Sirtuin R&D can only be a good thing for Genflow going forward. C'mon Eric , ready when you are!!! ;-)

Interestingly enough, Estee Lauder's new longevity product is the patented Sirtivity-LP technology, and appear to be investing heavily into the longevity space. Gla ;-)

From January 2024, the Estée Lauder Longevity Collective will serve as a brand advisory board, bringing new insights, research findings and resources to inform the brand’s ongoing approach to skin longevity research.

Collective members include Dr Nadine Pernodet, the brand’s Senior Vice President, Bioscience, Global R&D; long-term Estée Lauder partner Dr Danica Chen, Professor of Metabolic Biology, Nutritional Sciences & Toxicology at the University of California Berkeley; and Serena Liang Jing, a ‘New Map of Life’ Fellow at the Stanford Center on Longevity.

Experts from the Buck Institute for Research on Aging, the Center of Aging Research & Clinical Care at Weill Cornell Medicine, and the Stanford University School of Medicine will also be involved.

Next month will further see Estée Lauder launch Re-Nutriv Ultimate Diamond Transformative Brilliance Soft Crème.

The new sku is made with the brand’s patented Sirtivity-LP technology, which reveals visible age reversal starting at 14 days of use.

It is said to be the result of two decades of Estée Lauder’s study into the role of sirtuins – commonly known as ‘longevity proteins’ – in skin.

“The Estée Lauder brand has always been at the forefront of skin science,” said Justin Boxford, Global Brand President, Estée Lauder.

https://cosmeticsbusiness.com/est%C3%A9e-lauder-targets-age-reversal-with-stanford-center

The Future Is Bright

To a certain extent, the things you can do now to prevent premature aging is to live a healthy lifestyle that limits stress, follow a healthy diet, exercise regularly, and so on.

Fortunately, the future’s looking bright with medical biotechnological advancements.

Genflow Biosciences works with major anti-aging research centers across the globe and believes that the SIRT6 gene is a master regulator of managing healthy aging and the potential therapeutic target preserve function.

These discoveries are in pursuit of finding disruptive anti-aging drugs. In fact, clinical testing is starting to happen, albeit in the infancy stages, making way for potentially transformative medicines.

hTtps://genflowbio.com/premature-aging/

GenFlow Biosciences

1,399 followers

1h

At GenFlow Biosciences (LSE: GENF)(OTCQB: GENFF), we're passionate about unveiling the mysteries of aging. Our latest article dives deep into premature aging, offering valuable insights on how your lifestyle choices and genetic factors play a crucial role. Learn about the impacts on various body systems and get expert tips for staying youthful and healthy.

Read it here: htTps://loom.ly/565AscQ

#longevity #aging #healthspan

GenFlow Biosciences

1,399 followers

21h

In Sardinia, GenFlow Biosciences (LSE: GENF)(OTCQB: GENFF) is initiating a pioneering human proof-of-concept Phase I/II trial for Werner Syndrome, which serves as a model for studying premature aging in humans. Investigating its causes offers valuable insights into the aging process and may lead to strategies that enhance overall health and longevity.

Learn more about Werner here:

htTps://loom.ly/RcDWpwk #Werner #longevity #aging #healthspan

The date in the URL link below is November 2023, no doubt following the news of the appointment of the Joint Broker, and as good news could drop at anytime , it looks like there's going to be plenty of UPward momentum in sp in anticipation...Excitement building!!! Gl ;-)

Genflow Corporate Power Point Presentation

hTtps://genflowbio.com/wp-content/uploads/2023/11/GENF.corporate.US_.v1sm.pdf

The FDA are moving closer to award full approval ( trial result dependent ) for a longeity drug for dogs, so highly significant for Genflow's GF-4001 Non-Human Pipeline Anti-aging for veterinary use (dogs) and every chance we could get confirmation of the planned Pivotal trial anti-aging for dogs and an announcement of a JV Veterinary partner. Gla ;-)

29/11/3

A San Francisco-based biotechnology firm is on a mission to keep your best friend around a little longer.

Loyal is spearheading the development of an experimental drug geared toward extending the lifespan of large-breed dogs by a minimum of one year. On Tuesday, it secured conditional approval for its medication from the U.S. Food and Drug Administration.

The landmark approval clears the way for more extensive clinical trials. It also marks the first time the agency has endorsed a longevity drug.

hTtps://www.sfchronicle.com/sf/article/s-f-startup-wants-help-dogs-live-longer-got-fda-18522309.php

Looks like UK Biotech is hot hot hot this year and Genflow's tiny market cap looks extremely attractive commensurate to near term news and exciting prospects and potential going forward, in run up to human trials 2025!!! Gla :-)